Naltrexone

"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Descriptor ID	D009271
MeSH Number(s)	D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
Concept/Terms	Naltrexone Naltrexone Celupan Celupan Trexan Trexan Naltrexone Hydrochloride Naltrexone Hydrochloride Hydrochloride, Naltrexone ReVia ReVia Nemexin Nalorex Antaxone Antaxone EN-1639A EN-1639A EN 1639A EN1639A

Below are MeSH descriptors whose meaning is more general than "Naltrexone".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Naloxone [D03.132.577.249.706]
Naltrexone [D03.132.577.249.706.550]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Naloxone [D03.605.497.750]
Naltrexone [D03.605.497.750.550]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Naloxone [D03.633.400.686.750]
Naltrexone [D03.633.400.686.750.550]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Naloxone [D04.615.723.795.706]
Naltrexone [D04.615.723.795.706.550]

Below are MeSH descriptors whose meaning is related to "Naltrexone".

Below are MeSH descriptors whose meaning is more specific than "Naltrexone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.

Bar chart showing 62 publications over 20 distinct years, with a maximum of 12 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
2007	0	2	2
2008	3	1	4
2009	0	1	1
2010	0	1	1
2011	1	1	2
2012	4	0	4
2013	2	0	2
2014	2	1	3
2015	3	0	3
2016	1	2	3
2017	9	3	12
2018	3	5	8
2019	1	0	1
2020	1	2	3
2021	0	1	1
2022	0	2	2
2023	0	2	2
2024	1	2	3
2025	1	3	4

Below are the most recent publications written about "Naltrexone" by people in Profiles.

Friedmann PD, Wilson D, Stopka TJ, Bernson D, Pivovarova E, Ferguson W, Hoskinson RA, Rottapel RE, Bovell-Ammon B, Gaba A, Morgan JR, Senst T, Hayes E, Evans EA. Medications for Opioid Use Disorder in County Jails - Outcomes after Release. N Engl J Med. 2025 Sep 11; 393(10):994-1003.

View in: PubMed
Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Anderson J, Osilla KC, Ryzewicz S, Huerta S, Mazer MW, Hoskinson RA, Garvey R, Peltz A, Watkins KE, Nuckols T, IsHak WW, Mariano LT, Danovitch I. Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial. JAMA Intern Med. 2025 Jun 01; 185(6):624-633.

View in: PubMed
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 04 01; 8(4):e255340.

View in: PubMed
Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Aug; 120(8):1634-1645.

View in: PubMed
Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.

View in: PubMed
Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 07; 119(7):1313-1321.

View in: PubMed
Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.

View in: PubMed
Bailey A, Senthilkumar R, Evans EA. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail. J Addict Med. 2023 Sep-Oct 01; 17(5):568-573.

View in: PubMed
Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani RWMA, Potee RA, Ryan D, Murphy SM, Walley AY, Linas BP. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Netw Open. 2023 04 03; 6(4):e237036.

View in: PubMed
Shayan M, Eslami F, Amanlou A, Solaimanian S, Rahimi N, Rashidian A, Ejtemaei-Mehr S, Ghasemi M, Dehpour AR. Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or KATP channels inhibitors. Toxicol Appl Pharmacol. 2022 11 01; 454:116254.

View in: PubMed

People

Explore

Similar Concepts

Top Journals